# Elotuzumab, Daratumumab, Iberdomide, and Dexamethasone for the Treatment of Relapsed Multiple Myeloma

> **NCT06785415** · PHASE1,PHASE2 · RECRUITING · sponsor: **Mayo Clinic** · enrollment: 37 (estimated)

## Conditions studied

- Recurrent Multiple Myeloma

## Interventions

- **PROCEDURE:** Bone Marrow Aspiration
- **PROCEDURE:** Bone Marrow Biopsy
- **PROCEDURE:** Bone Scan
- **PROCEDURE:** Chest Radiography
- **PROCEDURE:** Computed Tomography
- **BIOLOGICAL:** Daratumumab
- **DRUG:** Dexamethasone
- **BIOLOGICAL:** Elotuzumab
- **DRUG:** Iberdomide
- **PROCEDURE:** Magnetic Resonance Imaging
- **PROCEDURE:** Positron Emission Tomography

## Key facts

- **NCT ID:** NCT06785415
- **Lead sponsor:** Mayo Clinic
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-03-18
- **Primary completion:** 2031-04-01
- **Final completion:** 2031-04-01
- **Target enrollment:** 37 (ESTIMATED)
- **Last updated:** 2025-09-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06785415

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06785415, "Elotuzumab, Daratumumab, Iberdomide, and Dexamethasone for the Treatment of Relapsed Multiple Myeloma". Retrieved via AI Analytics 2026-07-04 from https://api.ai-analytics.org/clinical/NCT06785415. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*